Insilico, US Firm to Develop AI Models Predicting Disease Decades Ahead

Hong Kong-listed AI drug-discovery company Insilico Medicine partnered with US-based Human Longevity to co-develop AI models predicting diseases like cancer decades before symptoms appear.

Wed May 27 2026

Collaboration for AI-Powered Disease Prediction Models

Hong Kong-listed Insilico Medicine, an artificial intelligence drug-discovery company, has announced a partnership with US-headquartered Human Longevity. The collaboration aims to co-develop what they describe as "the industry's first large-scale" AI foundation models capable of predicting diseases, such as cancer, decades before clinical symptoms appear.

Growth of the Global Longevity Market

This partnership comes as the global longevity market is valued at approximately US$5.3 trillion. This growth is fueled by an aging population and rising consumption demand. Both companies aim to leverage artificial intelligence to innovate in the field of early disease prediction and prevention.

*Source: SCMP (2026-05-27)*

Tags: #ai #disease-prediction #insilico-medicine #human-longevity #tech